See all ISLT articles at Daily Dose.
Islet Sciences, Inc. (OTCBB: ISLT) is a development-stage biotechnology company with patented technologies focused on transplantation therapy for people with insulin-dependent diabetes. The Company's transplantation technology includes methods for the culturing, isolation, maturation, and immuno-protection (microencapsulation) of islet cells. Islet Sciences’ mission includes the introduction of commercial products with applications to cell-based replacement therapy in the healthcare marketplace. The traditional treatment for Type 1 diabetes involves daily "fingerstick" monitoring of blood glucose levels throughout the day, with multiple daily injections of insulin or its continuous infusion. This approach does not cure the disease nor its complications, and often is associated with poor blood glucose control, which has a long-term deleterious effect on major organs.
Pre-Clinical Studies have demonstrated Islet Sciences-PTM’s potential clinical value for patients by:
- Reducing need for insulin
- Achieving better glucose stability
- Reducing problems with hypoglycemia (low blood sugar)
Islet Sciences plans to submit its IND in Q1, 2012 followed by human Phase I /IIA clinical trials.
ISLT Keywords
- Changing diabetes
- Changing the way diabetes is treated
- Islet transplant
- Type 1 diabetes transplant
- Insulin Dependent Diabetes
- Diabetes complications
- Diabetes Islet cell transplant
- Islet cell transplant
- Islet cell transplantation
